Key result
Emergency use of the Occlutech® Atrial Flow Regulator facilitated weaning from veno-arterial extracorporeal membrane oxygenation in a 35-year-old female with severe pulmonary arterial hypertension.
Why the study?
Atrial septostomy is underrecognized for symptomatic PAH on maximal therapy, and creating a sustainable, restrictive atrial communication is challenging with existing devices.
Does the Occlutech Atrial Flow Regulator device facilitate weaning from veno-arterial extracorporeal membrane oxygenation in a patient with severe pulmonary arterial hypertension?
Case Report (n=1)
Does the Occlutech Atrial Flow Regulator device facilitate weaning from veno-arterial extracorporeal membrane oxygenation in a patient with severe pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
The Occlutech Atrial Flow Regulator device may be a viable option to create a sustainable atrial communication and facilitate weaning from VA-ECMO in patients with severe pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Treatment options include anti-PAH medications, continuous intravenous therapies, and diuretics. Lung transplant is required in many cases. Atrial septostomy is an under recognized option in symptomatic patients on maximal PAH therapy. However, creating a sustainable and restrictive atrial communication is challenging with existing devices. We describe emergency use of the Occlutech ® Atrial Flow Regulator, a novel device, in a 35-year-old female with PAH supported on veno-arterial extracorporeal membrane oxygenation after postpartum decompensation.
No takes yet. Share an insight, caveat, or question.
Aregullin et al. (2021) conducted a case report in Severe Pulmonary Arterial Hypertension (n=1). Occlutech® Atrial Flow Regulator was evaluated on Weaning from veno-arterial extracorporeal membrane oxygenation. Emergency use of the Occlutech® Atrial Flow Regulator facilitated weaning from veno-arterial extracorporeal membrane oxygenation in a 35-year-old female with severe pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: